Clopidogrel Market - Global Industry Analysis, Size, Share, Trends and Forecast 2017 - 2025
Clopidogrel has remained, ever since its first approval in 1997, the antiplatelet therapy of choice among physicians for the treatment of patients with conditions such as acute coronary syndrome or percutaneous coronary intervention. The drug was the first thienopyridine to hit the market, which gave it an excellent head start over a number of drugs for these conditions that are either available in the market or are in clinical trials. As a result, the drug did not face much competition and has taken over the global market, with its array of application constantly expanding.
The substantial and high-level evidence gathered over the years support the use of Clopidogrel for reduction of mortality and morbidity patients with acute coronary syndrome, myocardial infarction, and a number of other indications. As a result, the drug has developed a formidable presence in the global market over the years. Moreover, the drug’s relative ease of use, low rate of incidence of adverse reactions, and good tolerability have made it the de-facto antiplatelet agent for the reduction of atherosclerotic events in patients.
These factors have helped the global Clopidogrel market to tread along an excellent growth path in the past few years and the market is expected to embark upon a healthy growth path in the next few years as well. However, the overall profitability of the market has reduced to a certain extent owing to entry of a number of generic products post the patent expiry of Clopidogrel manufacture in 2013. Nevertheless, the vast pool of patients prescribed Clopidogrel on an annual basis across the globe will allow market players excellent growth prospects in the next few years.
Clopidogrel is an antiplatelet agent of thienopyridine, which is primarily used to prevent the blood clots and help against cardiovascular problems associated with the blood clotting. The medications for inhibiting blood clots after a recent heart stroke also use clopidogrel, which is a white colored powder that is insoluble in water at neutral pH but freely soluble at pH1. Clopidogrel was the second most successful drug trailing behind Pfizer’s Lipito in 2010. Sold under the brand name Plavix, and marketed by Sanofi and Bristol-Myers Squibb, the demand for clopidogrel is escalating due to the increasing number of heart attack cases across the globe.
The patent of clopidogrel manufacturing got expires on Market 31, 2012 and is expected to prompt pharmaceutical companies to venture into clopidogrel drug manufacturing. Moreover, companies such as Dr. Reddy’s have acquired the approval to manufacture clopidogrel 300mg. Furthermore, several other organizations such as Roxane Laboratories, Aurobindo Pharma, Sun Pharma, Torrent Pharmaceuticals, and Apotex Crop have gained approval for marketing clopidogrel 75mg. Clopidogrel is also used with aspirin to treat worsening chest pain and to keep blood vessels open and present blood clots after certain heart related operations.
The primary factor for the increased demand for clopidogrel is the mounting population across the world who are suffering from cardiovascular diseases and related problems. Additionally, the changing lifestyle and increase in number of patients related with cardiovascular diseases among the emerging economies in the Asia Pacific region are also expected to be the major consumers for clopidogrel in the next six years. Moreover, the patent expiry of clopidogrel drug is anticipated to open floodgates for various pharmaceutical companies to venture into production of clopidogrel drug.
According to the World Heart Federation, nearly 15 million people suffer from heart attack or related problems globally. Out of these, roughly six million of these patients die while another five million are disabled permanently. This vast patient base is the primary factor that will sustain the demand during the forecast period.
Currently, North America and Europe contribute to the maximum demand for clopidogrel, owing to factors such as robust healthcare infrastructure and high affordability of the residents in this region. However, several countries in the region of Asia Pacific, such as China, India, and Japan are aggressively working towards improving their healthcare sector with the help of favorable policies by the localized governments and increasing disposable income among the urban population. Asia Pacific is home for nearly half of the world’s population, which makes for a high quantity of patient base. Additionally, these regions also have skilled labor at low cost which is encouraging players in the market to invest actively and tap the unmet demand.
Some of the key players in the global clopidogrel market are Pfizer, Dr Reddy’s, Apotex Corp, Roxane Laboratories, Aurobindo Pharma, Torrent Pharmaceuticals and Sun Pharma.
This study provides a particularized anatomy according to the L.E.A.P mechanism
The regional analysis offers market assays across:
The study, prepared through the L.E.A.P mechanism adds a dimension of infallibility and assures precise information on all the growth dynamics.
Latest Trends and Cardinal Growth Prospects
The study assists in burnishing the knowledge of the stakeholder in terms of the emerging trends. The study provides an expansive coverage on the latest developments and novel profit-yielding sources that augur well with the market. A dedicated and determined team of experts conduct an out-and-out research on diverse aspects to offer ultimate breakthroughs in the market.
Existing and Future Insights in Growth
The interfusion of ubiquitous primary and secondary research through modern tools invites perfection and accuracy in every aspect. Primary research is circumspectly conducted through exhaustive interactions and interviews of experts. These valuable opinions are then neatly inducted in the report to allow the stakeholder for reaping the benefits. A treasure of secondary data is extracted via famed paid sources, yearly estimates and statements, renowned journals, and government documents. These sources assist in creating a robust database comprising existing and subsequent growth dynamics.
Ascensions in Technology
Diverse technological advancements and cutting-edge innovations in the market have been covered in this study to assist the stakeholder in research and development activities. Recent upgrades have also been added in the study, thus helping the stakeholder to paint the strokes of growth on the canvas of the market.
The study presents a plethora of challenges and obstacles that can hinder the growth of the market to allow the stakeholder to prepare their strategies accordingly.
The world ushered in the new decade with the shadow of the COVID-19 pandemic. The outbreak has damaged the growth prospects of several businesses and has crippled the entire economy. The study is in tandem with the changing dynamics of the market due to the SARS-CoV-2 outbreak. The study focuses on the coronavirus pandemic and analyses every aspect that impacts the growth positively or negatively.
An aerial perspective of the regions covered in this study enables the stakeholder to design strategies accordingly. The 360-degree assessment of every aspect associated with growth offers information on a rainbow of growth opportunities available across the market.
The exhaustive study motivates the stakeholder to take the 'LEAP' of faith and achieve success!
This report is the key to questions such as:
What are the prominent factors that will help in reshaping the market growth?
Which trends have the potential to bring expansive growth for the market?
What are the necessary strategies to overcome the ill-effects of the COVID-19 pandemic?
Which regions will emerge as champion growth contributors for the market?
Which aspects will serve as game-changers for the market?
What are the latest innovations in the market?
Which factors will hinder the growth of the market?
Flat 10% discount on Single User License if you prebook this report
Flat 10% discount on Multiple User License if you prebook this report
Flat 10% discount on Corporate License if you prebook this report